AstraZeneca sales jump despite troubles in China
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It also cited annual budget caps at Chinese hospitals.
AstraZeneca faces potential fines in China
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
A Liberal Democrat peer has accused the government of favouring the south-east of England over Merseyside after AstraZeneca ...
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
(Reuters) -Strong results from AstraZeneca helped London's blue-chip index notch a record close on Thursday, while a dovish ...
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback